ISTH 2025 Was Hot—in More Ways Than One!

ISTH 2025 brought the heat this year—both in scientific content and in temperature! While Washington, D.C. was under a heat advisory during the 33rd Congress of the International Society on Thrombosis and Haemostasis, that didn’t stop thousands of dedicated clinicians, researchers, and industry professionals, including a large team from DiaPharma, from coming together for an outstanding meeting.

We had a fantastic time connecting with attendees in the Exhibition Hall and appreciated every conversation. Here are just a few of the highlights that stood out to our team:

Emerging Hemophilia Therapies

• Next-generation FVIII mimetics like Mim8, Inno8, and trispecific nanobodies are revolutionizing treatment paradigms and monitoring strategies. The complexities of testing algorithms are clear. We expect that labs will become even more attuned to if their chromogenic FVIII assays include bovine or human reagents. We also wonder if “this is the time” for thrombin generation assays? When non-factor reagents are given for prophylaxis, it is intriguing to assess a global view of hemostasis. 
• Oral prophylaxis options and novel delivery platforms are paving the way for more convenient, less invasive treatment alternatives—offering patients and families welcome relief from frequent intravenous infusions.

Fibrinolysis and Stroke Research

• Plasmin generation assays are gaining traction as potential predictors of arterial thrombosis in chronic kidney disease, signaling growing interest in the role of fibrinolysis.
• Combining tPA with NET-targeting therapies (such as DNase and DINAC) is showing promise for improving outcomes in ischemic stroke and deepening our understanding of fibrinolytic pathways.
• An exciting take away is the promise of rADAMTS13 in the area of stroke research. Could the deficiency of ADAMTS13 activity, which has traditionally been thought of as confined to the rare disease of TTP, be more common than previously thought?

Innovations in Platelet Function Testing

• Advances in simplified flow cytometry and microfluidic technologies are enhancing our ability to detect platelet dysfunction—particularly in trauma patients and those with thrombocytopenia.
• Synthetic and bio-inspired platforms are on the horizon, with the potential to transform acute bleeding management.

Standardization and Multiplex Testing

• Efforts to develop multiplex hemostasis panels are gaining momentum, reflecting a critical need for faster and more reliable diagnostics.
• Initiatives to harmonize ADAMTS13 assays continue to take root. While there are more tests for activity and inhibitors than ever before, there remains just one IVD kit in the US market (Technozym ADAMTS13 Activity ELISA, 5450701-US). Furthermore, we are now seeing questions arise like how to increase access to quick turn-around-testing and patient care. We envision a future where patients will get a timely diagnosis of TTP and access to safe, effective therapies all closer to home.

Women’s Health in Hemostasis Diagnostics

• Growing awareness of the diagnostic inequities affecting women in hemostasis and thrombosis is driving important conversations and research.
• There’s increased emphasis on recognizing and acting on clinical opportunities to diagnose bleeding and thrombotic disorders earlier in women.
• An especially enlightening session was on thrombotic complications in pregnancy, with new data on the risk-benefit analysis of antithrombotic agents was presented. The discussion here was also thought-provoking regarding when to perform thrombophilia testing on high-risk OB patients.
• When it comes to bleeding tendency among women and girls, it seems there is still a long-haul to diagnosis. A network of clinicians with research focus and clinics dedicated to serving such populations and working in a cross-disciplinary manner with OB colleagues gives us hope for new breakthroughs.

These topics, and many more, sparked exciting ideas and meaningful conversations. We left ISTH energized by the science, inspired by the innovation, and grateful for the opportunity to connect with so many of you.

Thank you to everyone who visited us at the booth. We look forward to continuing the conversation and supporting your work in the clinic and laboratory in the months to come.

—The DiaPharma Team

ML-00-01231